I am a
Home I AM A Search Login

Papers of the Week


2022 Jul 08


Fundam Clin Pharmacol

The NMDA receptor antagonist ketamine exerts analgesic effects via modulation of the nitric oxide pathway.

Authors

Mahmoudzade S, Goudarzi S, Mohammad Jafari R, Shafaroodi H, Dehpour A R, Sanatkar M
Fundam Clin Pharmacol. 2022 Jul 08.
PMID: 35802650.

Abstract

Ketamine, an NMDA receptor antagonist, has been approved to have analgesic effects. It is known that nitric oxide pathway is involved in antinociception but with dual effects. In this study, we investigated the role of nitric oxide in ketamine-induced analgesia.